세계의 올리고뉴클레오티드 합성 시장 : 산업 규모, 동향, 기회, 예측, 제품 유형별, 용도별, 최종 사용자별, 지역별, 경쟁별(2020-2030년)

Oligonucleotide Synthesis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type, By Application, By End User, By Region and Competition, 2020-2030F

US $ 4,500 ￦ 6,197,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,500 ￦ 7,574,000

PDF and Excel (Multi-User License)

PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.

US $ 8,000 ￦ 11,017,000

PDF and Excel (Custom Research License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.

한글목차

세계의 올리고뉴클레오티드 합성 시장 규모는 2024년에 42억 6,000만 달러로 평가되었고, 2030년에는 89억 7,000만 달러에 이를것으로 예측되며, 예측 기간 중 CAGR은 13.21%를 나타낼 것으로 전망됩니다.

이 시장은 유전자 편집, 분자 진단, RNA 기반 치료와 같은 용도의 초석 역할을 하며 바이오 의약품 혁신을 발전시키는 데 중요한 역할을 합니다. 이 분야의 급속한 확장은 유전체학 및 맞춤 의학의 혁신과 밀접한 관련이 있으며, 이에 따라 고품질의 맞춤형 올리고뉴클레오티드에 대한 수요가 급증하고 있습니다. 제약 회사와 연구 기관이 RNA 치료제와 유전자 표적 치료에 점점 더 집중함에 따라 확장 가능하고 정밀한 올리고뉴클레오티드 합성에 대한 필요성이 계속 커지고 있습니다. 특히 북미와 유럽에서 진행되는 임상시험은 올리고뉴클레오티드 기반 치료의 범위가 넓어지고 있음을 잘 보여줍니다. 강력한 투자, 생명공학 협력의 증가, 합성 기술의 발전으로 이 시장은 지속적인 혁신과 글로벌 채택을 위한 입지를 다지고 있습니다.

시장 개요
예측 기간	2026-2030년
시장 규모(2024년)	42억 6,000만 달러
시장 규모(2030년)	89억 7,000만 달러
CAGR(2025-2030년)	13.21%
급성장 부문	치료제
최대 시장	북미

시장 성장 촉진요인

RNA 기반 치료제

주요 시장 과제

효율성 및 확장성

주요 시장 동향

치료의 발전

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 목소리

제5장 세계의 올리고뉴클레오티드 합성 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율 및 예측
  • 제품 유형별(합성 올리고뉴클레오티드 제품, 시약, 장비, 서비스)
  • 용도별(연구, 치료제, 진단)
  • 최종 사용자별(학술연구기관, 제약 및 생명공학 기업, 병원 및 진단연구소)
  • 지역별
  • 기업별(2024년)
• 시장 맵

제6장 북미의 올리고뉴클레오티드 합성 시장 전망

• 시장 규모와 예측
• 시장 점유율 및 예측
• 북미 : 국가별 분석
  • 미국
  • 캐나다
  • 멕시코

제7장 유럽의 올리고뉴클레오티드 합성 시장 전망

• 시장 규모와 예측
• 시장 점유율 및 예측
• 유럽 : 국가별 분석
  • 독일
  • 영국
  • 이탈리아
  • 프랑스
  • 스페인

제8장 아시아태평양의 올리고뉴클레오티드 합성 시장 전망

• 시장 규모와 예측
• 시장 점유율 및 예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 일본
  • 한국
  • 호주

제9장 남미의 올리고뉴클레오티드 합성 시장 전망

• 시장 규모와 예측
• 시장 점유율 및 예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 올리고뉴클레오티드 합성 시장 전망

• 시장 규모와 예측
• 시장 점유율 및 예측
• 중동 및 아프리카 : 국가별 분석
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향 및 발전

• 최근 동향
• 합병 및 인수

제13장 세계의 올리고뉴클레오티드 합성 시장 : SWOT 분석

제14장 Porter's Five Forces 분석

• 업계 내 경쟁
• 신규 진입의 가능성
• 공급자의 힘
• 고객의 힘
• 대체 치료법의 위협

제15장 경쟁 구도

• Thermo Fisher Scientific Inc
• Agilent Technologies, Inc.
• Merck KGaA
• BIO-Synthesis Inc
• Eurofins Scientific SE
• Danaher Corporation
• Ajinomoto Bio-Pharma Services
• Biogen Inc.
• Ionis Pharmaceuticals, Inc.
• Sarepta Therapeutics, Inc.

제16장 전략적 제안

제17장 기업 소개와 면책사항

HBR

영문 목차

영문목차

The Global Oligonucleotide Synthesis Market was valued at USD 4.26 billion in 2024 and is projected to reach USD 8.97 billion by 2030, growing at a CAGR of 13.21% during the forecast period. This market plays a vital role in advancing biopharmaceutical innovation, serving as a cornerstone for applications such as gene editing, molecular diagnostics, and RNA-based therapies. The sector's rapid expansion is closely tied to breakthroughs in genomics and personalized medicine, where demand for high-fidelity, tailor-made oligonucleotides has soared. As pharmaceutical companies and research institutions increasingly focus on RNA therapeutics and gene-targeting treatments, the need for scalable and precise oligonucleotide production continues to intensify. Clinical trials-particularly in North America and Europe-underscore the broadening scope of oligonucleotide-based treatments. With robust investments, growing biotech collaborations, and the evolution of synthesis technologies, the market is positioned for sustained innovation and global adoption.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 4.26 Billion
Market Size 2030	USD 8.97 Billion
CAGR 2025-2030	13.21%
Fastest Growing Segment	Therapeutics
Largest Market	North America

Key Market Drivers

RNA-Based Therapeutics

RNA-based therapeutics have emerged as a powerful tool for treating a wide range of diseases, propelling the demand for synthetic oligonucleotides. Applications like small interfering RNA (siRNA), antisense oligonucleotides (ASOs), and messenger RNA (mRNA) therapies rely on precise nucleotide synthesis. The global spotlight on mRNA vaccines-particularly those developed for COVID-19-has significantly increased awareness and investment in this segment. Beyond vaccines, RNA-based therapeutics are targeting chronic conditions and rare genetic disorders by altering or silencing specific gene expressions. These therapies require advanced oligonucleotide sequences manufactured with stringent quality and precision standards, highlighting the growing dependence on oligonucleotide synthesis for modern drug development pipelines.

Key Market Challenges

Efficiency and Scalability

Despite strong demand, the industry faces persistent challenges in scaling up oligonucleotide production without compromising quality. High-throughput synthesis processes require consistent optimization to maintain cost-effectiveness, especially as research moves from lab-scale to commercial-scale applications. Additionally, synthesizing complex, longer, or chemically modified oligonucleotides can be resource-intensive, requiring specialized equipment and infrastructure. Compliance with global regulatory standards adds another layer of complexity, necessitating rigorous quality controls. These hurdles can increase production timelines and costs, potentially slowing down commercialization, especially for startups and smaller biopharma companies.

Key Market Trends

Therapeutic Advancements

Therapeutic innovation remains a defining trend in the oligonucleotide synthesis market. The success of mRNA vaccines has validated RNA-based platforms, sparking a surge in R&D investments aimed at tackling conditions like cancer, neurodegenerative diseases, and rare genetic disorders. Oligonucleotides are central to these developments, forming the basis for antisense therapies, RNA interference (RNAi), and gene-editing technologies such as CRISPR. This growing reliance on synthetic nucleic acids has intensified efforts to develop faster, purer, and more cost-efficient synthesis technologies. As pharmaceutical pipelines increasingly include nucleic acid-based drugs, demand for specialized synthesis services and materials is expected to rise significantly, solidifying the sector's strategic importance in modern medicine.

Key Market Players

• Thermo Fisher Scientific Inc
• Agilent Technologies, Inc.
• Merck KGaA
• BIO-Synthesis Inc
• Eurofins Scientific SE
• Danaher Corporation
• Ajinomoto Bio-Pharma Services
• Biogen Inc.
• Ionis Pharmaceuticals, Inc.
• Sarepta Therapeutics, Inc.

Report Scope

In this report, the Oligonucleotide Synthesis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Oligonucleotide Synthesis Market, By Product Type:

• Synthesized Oligonucleotide Products
• Reagents
• Equipment
• Services

Oligonucleotide Synthesis Market, By Application:

• Research
• Therapeutics
• Diagnostics

Oligonucleotide Synthesis Market, By End User:

• Academic Research Institutes
• Pharmaceutical & Biotechnology Companies
• Hospital & Diagnostic Laboratories

Oligonucleotide Synthesis Market, By Region:

• North America
• United States
• Mexico
• Canada
• Europe
• France
• Germany
• United Kingdom
• Italy
• Spain
• Asia-Pacific
• China
• India
• South Korea
• Japan
• Australia
• South America
• Brazil
• Argentina
• Colombia
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Oligonucleotide Synthesis Market.

Available Customizations

Oligonucleotide Synthesis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Oligonucleotide Synthesis Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product Type (Synthesized Oligonucleotide Products, Reagents, Equipment, and Services)
  • 5.2.2. By Application (Research, Therapeutics, and Diagnostics)
  • 5.2.3. By End User (Academic Research Institutes, Pharmaceutical and Biotechnology Companies, and Hospital and Diagnostic Laboratories)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Oligonucleotide Synthesis Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product Type
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Oligonucleotide Synthesis Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product Type
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Oligonucleotide Synthesis Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product Type
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Oligonucleotide Synthesis Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product Type
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User

7. Europe Oligonucleotide Synthesis Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product Type
  • 7.2.2. By Application
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Oligonucleotide Synthesis Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product Type
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. United Kingdom Oligonucleotide Synthesis Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product Type
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. Italy Oligonucleotide Synthesis Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product Type
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. France Oligonucleotide Synthesis Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product Type
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Oligonucleotide Synthesis Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product Type
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. Asia-Pacific Oligonucleotide Synthesis Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product Type
  • 8.2.2. By Application
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Oligonucleotide Synthesis Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product Type
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. India Oligonucleotide Synthesis Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product Type
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Oligonucleotide Synthesis Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product Type
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Oligonucleotide Synthesis Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product Type
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Oligonucleotide Synthesis Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product Type
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End User

9. South America Oligonucleotide Synthesis Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product Type
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Oligonucleotide Synthesis Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product Type
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina Oligonucleotide Synthesis Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product Type
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia Oligonucleotide Synthesis Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product Type
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. Middle East and Africa Oligonucleotide Synthesis Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product Type
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Oligonucleotide Synthesis Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product Type
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia Oligonucleotide Synthesis Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product Type
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. UAE Oligonucleotide Synthesis Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product Type
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions

13. Global Oligonucleotide Synthesis Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Treatment Types

15. Competitive Landscape

• 15.1. Thermo Fisher Scientific Inc
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Agilent Technologies, Inc.
• 15.3. Merck KGaA
• 15.4. BIO-Synthesis Inc
• 15.5. Eurofins Scientific SE
• 15.6. Danaher Corporation
• 15.7. Ajinomoto Bio-Pharma Services
• 15.8. Biogen Inc.
• 15.9. Ionis Pharmaceuticals, Inc.
• 15.10. Sarepta Therapeutics, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer

관련자료